Semaglutide, known commercially as Ozempic and Wegovy, is a GLP-1 receptor agonist that has become well-known for its ability to manage type 2 diabetes and promote weight loss
IRS Publication 502 provides the official definition of qualified medical expenses for HSA and FSA reimbursement, including prescription medications and treatments prescribed by licensed providers
In naturally aged mouse models (1820 months old), daily oral administration of 5-amino-1mq capsules for 12 consecutive weeks significantly reduced NNMT activity and increased NAD+ levels in various tissues (liver, kidney, adipose tissue), along with markedly elevated expression of SIRT1 and SIRT3 proteins
Over the last decade, several studies have investigated the role of glucose-lowering drugs in cardiovascular outcomes, especially glucagon-like peptide-1 receptor agonists (GLP1-RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) which have demonstrated substantial improvements in major cardiovascular events, kidney function outcomes, and hospitalizations [3]
GLP-1: Key to Blood Glucose Homeostasis GLP-1 is part of a group of metabolic hormones called incretin hormones that help decrease blood glucose levels
